Bunsow De Mory founder and managing partner Denise De Mory and firm Counsel Li Guo published in Law360 a review of the Federal Circuit’s key decisions handed down in June 2024. These decisions highlighted a potential path for branded drugmakers to sue generic-drug makers for off-label uses of their skinny-labeled products, illustrated the need to be rigorous in documenting trade secret claims underlying a request for a preliminary injunction, provided helpful reminders about IPR practice and highlighted the potential downsides of violating a pretrial order offering testimony beyond that allowed by the court.
You can read the article here (subscription required).